Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Lakefront Biotherapeutics NV (NASDAQ: LKFT)
LKFT Stock Predictions and Ratings
WSX Rating:
BUY
WSX Forecast (1yr):
8.10%
Analyst Rating:
NOT AVAILABLE
Analyst Forecast (1yr):
NOT AVAILABLE
LKFT Stock Analysis
LKFT
PE Ratio:
3.2
LKFT
PEG Ratio:
Not Available
LKFT
Forward EPS Growth (12 month):
0.00%
LKFT
PS Ratio:
1.6
LKFT
PSG Ratio:
-0.2
LKFT
Forward Revenue Growth (12 month):
-6.70%
LKFT Articles
No data was found